2012    /    2011    /    2010     /     2009     /     2008     /     2007

“Anticipated start for the year”

Published on 24 April 2012

Orion’s sales developed well in the first months of the year. Our total net sales were slightly higher, even though sales of our Parkinson’s drugs were as anticipated about 14 per cent lower than in the corresponding period in 2011, which had also included a non-recurring milestone payment of EUR 7 million. Sales of our Specialty Products grew strongly, as did Fermion and Orion Diagnostica sales. During the quarter we also made the first deliveries of generic entacapone products to North America.

“Launching of Dexdor intensive care sedative in Europe has progressed as planned and the product is already available in over ten European countries. The product will be launched in most other European countries in 2012 as pricing and reimbursement processes progress country by country.

“Our delivery capability, especially in Finland, was slightly below normal at the beginning of the year following the fire at the Turku manufacturing plant at the end of 2011, although operations at the plant returned to normal during the first months of the year. However, the financial effects of the incident remained relatively small.

“Our research projects have progressed as planned. The study results on a new Easyhaler budesonide-formoterol formulation received early in 2012 were promising, but not yet sufficient for submission of an application for marketing authorisation. During the year we will continue developing it and an Easyhaler fluticasone-salmeterol formulation, as well as developing other molecules in clinical trial phase.
“Our outlook estimate, which can be found with the basis for it on pages 5–6 of this report, remains unchanged. We estimate that our net sales will be at similar level to 2011 and our operating profit at similar level to 2010. In 2011, our net sales were EUR 918 million and in 2010 our operating profit was EUR 254 million. ”